Gujarat Themis Biosyn DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025


0.75×	0.75×	0.74×
0.96×	0.99×	1.03×
38.9%	37.8%	42.1%
0.41×	0.41×	0.50×
1.75×	1.75×	1.21×
20.1%	20.2%	19.6%
17.4%	17.4%	19.6%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

GUJTHEM₹375.80

Gujarat Themis Biosyn Limited

· Pharma & Health

₹ CrorePeersRPGLIFE GUFICBIO ORCHPHARMA UNICHEMLAB FDC IOLCP MOREPENLAB INNOVACAPMcap ₹4,095 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.74	0.75	0.75
Interest Burden (Pretax/EBIT) ×	1.03	0.99	0.96
EBIT Margin %	42.09	37.76	38.88
Asset Turnover ×	0.50	0.41	0.41
Financial Leverage (Assets/Equity) ×	1.21	1.75	1.75
ROE (5-step product, year-end total equity) %	19.62	20.19	20.10
ROE (owners' profit / average owners' equity) %	19.64	17.41	17.41

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.